These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 21733283)

  • 1. D-serine adjuvant treatment alleviates behavioural and motor symptoms in Parkinson's disease.
    Gelfin E; Kaufman Y; Korn-Lubetzki I; Bloch B; Kremer I; Javitt DC; Heresco-Levy U
    Int J Neuropsychopharmacol; 2012 May; 15(4):543-9. PubMed ID: 21733283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pilot controlled trial of D-serine for the treatment of post-traumatic stress disorder.
    Heresco-Levy U; Vass A; Bloch B; Wolosker H; Dumin E; Balan L; Deutsch L; Kremer I
    Int J Neuropsychopharmacol; 2009 Oct; 12(9):1275-82. PubMed ID: 19366490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
    Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C
    Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability.
    Smith KM; Eyal E; Weintraub D;
    JAMA Neurol; 2015 Jan; 72(1):88-95. PubMed ID: 25420207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia.
    Weiser M; Heresco-Levy U; Davidson M; Javitt DC; Werbeloff N; Gershon AA; Abramovich Y; Amital D; Doron A; Konas S; Levkovitz Y; Liba D; Teitelbaum A; Mashiach M; Zimmerman Y
    J Clin Psychiatry; 2012 Jun; 73(6):e728-34. PubMed ID: 22795211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor.
    Lane HY; Lin CH; Green MF; Hellemann G; Huang CC; Chen PW; Tun R; Chang YC; Tsai GE
    JAMA Psychiatry; 2013 Dec; 70(12):1267-75. PubMed ID: 24089054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.
    Olié JP; Spina E; Murray S; Yang R
    Int Clin Psychopharmacol; 2006 May; 21(3):143-51. PubMed ID: 16528136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
    Barone P; Poewe W; Albrecht S; Debieuvre C; Massey D; Rascol O; Tolosa E; Weintraub D
    Lancet Neurol; 2010 Jun; 9(6):573-80. PubMed ID: 20452823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of N-methyl-D-aspartate receptor glycine site temporally ameliorates neuropsychiatric symptoms of Parkinson's disease with dementia.
    Tsai CH; Huang HC; Liu BL; Li CI; Lu MK; Chen X; Tsai MC; Yang YW; Lane HY
    Psychiatry Clin Neurosci; 2014 Sep; 68(9):692-700. PubMed ID: 24612097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia.
    Kremer I; Vass A; Gorelik I; Bar G; Blanaru M; Javitt DC; Heresco-Levy U
    Biol Psychiatry; 2004 Sep; 56(6):441-6. PubMed ID: 15364042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quetiapine improves visual hallucinations in Parkinson disease but not through normalization of sleep architecture: results from a double-blind clinical-polysomnography study.
    Fernandez HH; Okun MS; Rodriguez RL; Malaty IA; Romrell J; Sun A; Wu SS; Pillarisetty S; Nyathappa A; Eisenschenk S
    Int J Neurosci; 2009; 119(12):2196-205. PubMed ID: 19916848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.
    Rascol O; Fitzer-Attas CJ; Hauser R; Jankovic J; Lang A; Langston JW; Melamed E; Poewe W; Stocchi F; Tolosa E; Eyal E; Weiss YM; Olanow CW
    Lancet Neurol; 2011 May; 10(5):415-23. PubMed ID: 21482191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia.
    Möller HJ; Riedel M; Jäger M; Wickelmaier F; Maier W; Kühn KU; Buchkremer G; Heuser I; Klosterkötter J; Gastpar M; Braus DF; Schlösser R; Schneider F; Ohmann C; Riesbeck M; Gaebel W
    Int J Neuropsychopharmacol; 2008 Nov; 11(7):985-97. PubMed ID: 18466670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration.
    Rabey JM; Prokhorov T; Miniovitz A; Dobronevsky E; Klein C
    Mov Disord; 2007 Feb; 22(3):313-8. PubMed ID: 17034006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.
    de Lucena D; Fernandes BS; Berk M; Dodd S; Medeiros DW; Pedrini M; Kunz M; Gomes FA; Giglio LF; Lobato MI; Belmonte-de-Abreu PS; Gama CS
    J Clin Psychiatry; 2009 Oct; 70(10):1416-23. PubMed ID: 19906345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial.
    Möller HJ; Riedel M; Müller N; Fischer W; Kohnen R
    Pharmacopsychiatry; 2004 Nov; 37(6):270-8. PubMed ID: 15551193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuro-psychiatric therapy during chronic subthalamic stimulation in Parkinson's disease.
    Zibetti M; Pesare M; Cinquepalmi A; Rosso M; Castelli L; Rizzi L; Bergamasco B; Lanotte M; Lopiano L
    Parkinsonism Relat Disord; 2009 Feb; 15(2):128-33. PubMed ID: 18515169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial.
    Goetz CG; Damier P; Hicking C; Laska E; Müller T; Olanow CW; Rascol O; Russ H
    Mov Disord; 2007 Jan; 22(2):179-86. PubMed ID: 17094088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of non-motor symptoms on health-related and perceived quality of life in Parkinson's disease.
    Santos-García D; de la Fuente-Fernández R
    J Neurol Sci; 2013 Sep; 332(1-2):136-40. PubMed ID: 23890935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial.
    Ory-Magne F; Corvol JC; Azulay JP; Bonnet AM; Brefel-Courbon C; Damier P; Dellapina E; Destée A; Durif F; Galitzky M; Lebouvier T; Meissner W; Thalamas C; Tison F; Salis A; Sommet A; Viallet F; Vidailhet M; Rascol O;
    Neurology; 2014 Jan; 82(4):300-7. PubMed ID: 24371304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.